SCYNEXIS (SCYX) Registration filing summary

Company overview and business model

• Clinical-stage biotech focused on severe rare diseases, notably ADPKD and antifungal therapies.

• Lead assets include SCY-770 (for ADPKD, Orphan Drug Designation) and SCY-247 (antifungal, Fast Track and Orphan Drug status).

• Commercial rights to ibrexafungerp (BREXAFEMME) licensed to GSK; SCY-247 and other compounds retained.

Financial performance and metrics

• Limited history of profitability; only one product approved and licensed out.

• Generated limited revenue from product sales to date.

Use of proceeds and capital allocation

• No proceeds from resale of shares by selling stockholders; proceeds only from cash exercise of warrants.

• Company bears registration costs; selling stockholders pay their own selling expenses.